Drugs / Iomazenil
Iomazenil
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01590277 | Dec 2012 → Nov 2018 | alcohol-induced mental disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 0 | NCT00982982 Comparator | Feb 2009 → Feb 2013 | schizophrenia | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT00611572 Comparator | Jan 2007 → Oct 2018 | cognitive disorder | Yale University | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iomazenil | “This project is looking at the substance iomazenil and its effect on alcohol intoxication and alcohol's effects on driving using a driving simulator.” NCT01590277 ↗ |
| Known as | Iomazenil, i-123 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110679 ↗ |
| Known as | RO 16-0154 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110679 ↗ |
| Modality | Small molecule | “benzodiazepine partial inverse agonist” NCT01590277 ↗ |
| Route | Intravenous | “Given as IV infusion” NCT00611572 ↗ |